Response to ustekinumab in three pediatric patients with alopecia areata.

Autor: Aleisa A; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts., Lim Y; Tufts School of Medicine, Tufts University, Boston, Massachusetts., Gordon S; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts., Her MJ; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts., Zancanaro P; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts., Abudu M; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts., Deverapalli SC; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts., Madani A; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts., Rosmarin D; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2019 Jan; Vol. 36 (1), pp. e44-e45. Date of Electronic Publication: 2018 Oct 18.
DOI: 10.1111/pde.13699
Abstrakt: Alopecia areata (AA) is relatively common and can have a significant impact on quality of life, especially in a pediatric population. Currently available treatments are often ineffective or have poor safety profiles. Recent studies have highlighted the importance of the Th1 pathway in the pathogenesis of AA, suggesting ustekinumab as a treatment modality for this disease. We present three pediatric AA patients who demonstrated hair regrowth after initiating ustekinumab.
(© 2018 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: